2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. (September 2015)

• Record Type: Journal Article
• Authors: Sepúlveda, J.M.; Vaz, M.A.; Gil, M.; Reynés, G.; Gallego, O.; Bolós, M.V.; Laýn, A. Hernádez; Sánchez-Gómez, P.; Martýnez, M.; Vicente, E.; Quindos, M.; Luque, R.; Ramos, A.; Ruano, Y.; Manneh, R.; Segura, P. Pérez; Benavides, M.; Balañá, C.
• Is Part Of: European journal of cancer. Volume 51:(2015)Supplement 3
• Page Start: S585
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(16)31619-7
• Languages: English
• ISSNs: 0959-8049